InMed Pharmaceuticals (INM) investor relations material

Executive summary

• The annual general and special meeting will be held virtually on December 17, 2025, to maximize shareholder participation and accessibility, with voting available by proxy, mail, fax, or online.

• Key matters include receiving audited financials, electing five directors, re-appointing the auditor, and approving a potential share issuance under a standby equity purchase agreement.

• The company uses notice-and-access provisions to reduce physical mailings, providing materials online and allowing shareholders to request paper copies.

Voting matters and shareholder proposals

• Shareholders will vote on electing five directors, re-appointing CBIZ CPAs P.C. as auditor, and approving the issuance of 20% or more of outstanding shares under the SEPA with YA II PN, Ltd.

• Shareholder proposals for the 2026 meeting must be received by June 30, 2026, to be included in proxy materials.

• The SEPA share issuance proposal is subject to Nasdaq rules and, if approved, may result in dilution but provides a flexible capital source.

Board of directors and corporate governance

• The board consists of five nominees, with four independent directors and one non-independent (the CEO).

• The board separates the roles of CEO and Chair, with the Chair being independent.

• Committees include Audit, Compensation, and Governance and Nomination, all composed of independent directors.

• The board has adopted policies on majority voting, insider trading, related party transactions, and a code of conduct.

• Board and committee meetings are held regularly, with high attendance and in-camera sessions for independent directors.